Azitra, Inc.

Azitra, Inc. announced a strategic reorientation, shifting its focus towards programs with near-term value-creating milestones, leveraging its microbial genetic engineering technology. This expansion, enabled by a $10.5 million financing in March, includes new initiatives in cosmetic ingredients (ATR-COSF) and biotechnology products (recombinant proteins). The company continues enrollment for its ATR-04 clinical program but has paused enrollment for ATR-12 to reallocate resources to the ATR-COSF program, which is expected to have clinical study results in late 2026.

Azitra, Inc. stockholders approved several key proposals at its reconvened 2026 Annual Meeting on June 15, 2026. Major approvals include increasing the authorized common stock from 200,000,000 to 750,000,000 shares and authorizing the Board to effect one or more reverse stock splits. Additionally, four director nominees were elected, and Grassi & Co., CPAs, P.C. was ratified as the independent auditor for the fiscal year ending December 31, 2026. Stockholders also approved the issuance of over 19.99% of common stock related to two separate securities purchase agreements from November 2025 and March 2026, but did not approve an amendment to the 2023 Stock Incentive Plan to increase its share reserve.

Azitra, Inc. adjourned its 2026 annual meeting of stockholders on June 4, 2026, without conducting any business, due to a lack of quorum. Only approximately 17% of outstanding shares were represented, falling short of the required 33 1/3%. The meeting will reconvene virtually on June 15, 2026, at 11:00 a.m. Eastern Time. The record date of April 24, 2026, and the proposals to be voted on remain unchanged, and stockholders who have already voted do not need to take further action.

Azitra, Inc. announced the adjournment of its 2026 annual meeting of stockholders, originally scheduled for June 4, 2026. The meeting will reconvene virtually on June 15, 2026, at 11:00 a.m. Eastern Time. This adjournment is to allow additional time for stockholders to receive and submit proxy materials following a minor administrative mailing delay. The record date for voting remains April 24, 2026, and the proposals to be voted on are unchanged.

Azitra, Inc. filed an S-1 registration statement for the resale of up to 255,699,381 shares of common stock by selling stockholders. These shares originate from a private placement that closed on March 20, 2026, involving Series A Preferred Stock and Series B and C Warrants. The company will not receive proceeds from the resale, but could receive approximately $21 million if all warrants are exercised for cash. The filing highlights substantial dilution for existing stockholders and a going concern warning from its independent registered public accounting firm.

Azitra, Inc. reported an increased net loss of $(3.93) million for the first quarter of 2026, compared to $(3.07) million in the same period last year. Despite the loss, the company significantly bolstered its liquidity, with cash and cash equivalents rising to $10.05 million and total stockholders' equity reaching $10.48 million. This improvement was largely driven by $10.38 million in net proceeds from a private placement and $10.4 million from a Series A Preferred Stock Offering. The company also disclosed a going concern warning and recorded $623,532 in impairment expenses for deferred patent costs.

Azitra, Inc. reported a net loss of $3.9 million for the first quarter of 2026, an increase from $3.1 million in the comparable period of 2025, with R&D and G&A expenses also rising. The company ended the quarter with $10.1 million in cash and cash equivalents. Operationally, Azitra made significant progress, including adding MD Anderson Cancer Center as a clinical site for its ATR-04 trial, launching new protein and peptide programs for cosmeceuticals, and securing a new U.S. patent for its lead product candidate, ATR-12. The company also priced a private placement financing of up to $10.5 million and expects key pipeline data in the second half of 2026.

Azitra, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026. Key proposals include increasing authorized common stock from 200 million to 750 million shares and authorizing the Board to effect one or more reverse stock splits. Stockholders will also vote on approving the issuance of over 19.99% of common stock for two separate securities purchase agreements to comply with NYSE American rules, electing four directors, ratifying the independent auditor, and increasing the share reserve for the 2023 Stock Incentive Plan.